英文版说明书 Mabthera Infusionskonzentrat 100mg/10ml 2 Ampullen 10mlFachinformationenZusammensetzungWirkstoff: Rituximabum.Hilfsstoffe: Natrii citras, polysorbatum 80 (aus gentechnisch verändertem Mais hergestellt), natrii chloridum, aqua ad iniectabilia.Galenische Form und Wirkstoffmenge pro Einh...
ACR, American College of Rheumatology; MTX, methotrexate; TNFi, tumor necrosis factor inhibitor.IMPORTANT SAFETY INFORMATION INDICATIONS Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA)...
rituximab-abbs (Truxima), rituximab-arrx (Riabni), and rituximab-pvvr (Ruxience). For information on site of service for these medications, seeUtilization Management Policy on Site of Care for Specialty Drug Infusions.
Patients were 18 years of age or older, diagnosed with active RA according to American College of Rheumatology (ACR) criteria, and had at least 8 swollen and 8 tender joints. In RA Study 1 (NCT00468546), patients were randomized to receive either RITUXAN 2×1,000 mg+MTX or placebo+MTX ...
doi:10.1002/acr2.11074 PubMedGoogle ScholarCrossref 44. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J ...
ACR, American College of Rheumatology; MTX, methotrexate; TNFi, tumor necrosis factor inhibitor. INDICATIONS Rituxan®(rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate...
Patients were 18 years of age or older, diagnosed with active RA according to American College of Rheumatology (ACR) criteria, and had at least 8 swollen and 8 tender joints. In RA Study 1 (NCT00468546), patients were randomized to receive either rituximab 2×1,000 mg+MTX or placebo ...
Methods A retrospective study of patients with SLE (ACR 1982 revised criteria) who were treated with RTX in the Department of Rheumatology at the Parc de Salut MAR (Barcelona, Spain). For each patient, demographic and clinical information was collected as well as number of cycles and possible ...
rituximab is clearly effective in certain autoimmune diseases, on the individual level clinical response may vary and is difficult to predict. one of the factors thought to contribute to this variability is the timing and depth of b cell depletion, which has been shown to be very patient ...
部份中文美罗华处方资料(仅供参考)药品英文名:Rituximab药品别名:美罗华、科妥昔单抗、MabThera、Rituxan药物剂型:注射剂,500mg(50ml),100mg(10ml)。药理作用:本品与纵贯细胞膜的CD20抗原特异性结合。该抗原位于前B细胞和成熟B淋巴细胞,但在造血干细胞、后B细胞、正常血浆细胞,或其他正常组织中不存在。该抗原表达于95...